TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04530747
Drug: Metformin + PAP
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Subjects randomized to this arm will receive 500 mg capsules containing metformin extended release (XR). Metformin XR dosing will be 500 mg (1 x 500 mg) every evening (qPM) during Week 1, 1000 mg (2 x 500 mg) qPM during Week 2, 1500 mg (3 x 500 mg) qPM during Week 3, and 2000 mg (4 x 500 mg) qPM from Week 4 onwards.~Subjects will also be provided PAP (positive airway pressure) device for standard management of obstructive sleep apnea.
Study: NCT06339281
Drug: apatinib mesylate+Fulvestrant injection
Normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Apatinib Mesylate Tablets: 500 mg, qd, orally until disease progression or intolerable adverse reactions.~Fulvestrant injection 500 mg, intramuscular injection, q4w, once on d1 and d15 in the first cycle;
Study: NCT05707520
Drug: None MPA
Normalized name: polyurethane-34 (55 MPA)
DrugBank: Urethane (DB04827)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunosuppression protocol without enteric-coated mycophenolate sodium
Study: NCT05576415
Drug: Varenicline Tartrate Nasal Spray
Normalized name: varenicline Nasal Spray
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal delivery of OC-01 (varenicline solution) 0.6 mg/mL twice a day (BID) for 28 days.
Study: NCT00002274
Drug: Didanosine
Normalized name: Didanosine
DrugBank: Didanosine (DB00900)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05103501
Drug: PF regimen (cis-platinum ; 5-fluorouracil ) combined with PD-1 inhibitors（pembrolizumab）
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: immunotherapy:PD-1 inhibitor chemotherapy:5-Fu and DDP
Study: NCT05297292
Drug: MW02
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: MW02 is a recombinant anti-VEGF humanized monoclonal antibody injection.
Study: NCT05297292
Drug: Lucentis
Normalized name: Lucentis
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: a recombinant anti-VEGF humanized monoclonal antibody injection
Study: NCT05749874
Drug: Berberine plus lifestyle intervention
Normalized name: berberine
DrugBank: Berberine (DB04115)
Approvals — FDA: no, EMA: no, PMDA: no
Description: berberine hydrochloride 500mg twice a day plus lifestyle intervention. Lifestyle intervention is based onChinese guideline on the primary prevention of cardiovascular diseases and Guideline for the prevention and treatment of type 2 diabetes mellitus in China (2020 edition), including health education on smoking, alcohol consumption, diet, physical activity and weight loss, etc.
Study: NCT04833049
Drug: TAK-994 Oral Tablet
Normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-994 tablet.
Study: NCT05714254
Drug: MEDI0618
DrugBank: MEDI0680 (DB15768)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four doses of 100 mg IV, 200 mg IV or 200 mg SC MEDI0618 administered once every two weeks.
Study: NCT05834270
Drug: Single dose tamsulosin 0.4mg
DrugBank: Tamsulosin (DB00706)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single dose tamsulosin 0.4mg
Study: NCT05834270
Drug: Double dose tamsulosin 0.4mg
DrugBank: Tamsulosin (DB00706)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Double dose tamsulosin 0.4mg
Study: NCT06524609
Drug: Epigallocatechin-3-Gallate
Normalized name: Epigallocatechin-3-gallate
DrugBank: Epigallocatechin gallate (DB12116)
Approvals — FDA: no, EMA: no, PMDA: no
Description: After determining the optimal dose, the efficacy of EGCG was compared with that of a control group (75% alcohol).
Study: NCT06524609
Drug: Alcohol
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: After determining the optimal dose, the efficacy of EGCG was compared with that of a placebo control group (75% alcohol).
Study: NCT06284642
Drug: Urokinase
Normalized name: Urokinase
DrugBank: Urokinase (DB00013)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: On the basis of standard treatment for severe neurological conditions, within 24 hours of aneurysm treatment, lumbar drainage combined with intrathecal urokinase injection was started. 30,000 IU urokinase dissolved in 3 ml normal saline was injected into the subarachnoid space, 3 ml normal saline was rinsed into the tube, and the tube was clamped for observation for 2 hours, once a day, for 3 consecutive days. Lumbar cisternae drainage Cerebrospinal fluid is slowly and steadily drained at a rate of less than 8ml/h per hour, the daily drainage volume is not more than 200 ml, and the drainage time of lumbar cisternae is controlled within 7 to 10 days, not more than 14 days.
Study: NCT05546359
Drug: Amisulpride Injection
Normalized name: amisulpride Injection
DrugBank: Amisulpride (DB06288)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose finding treatment for continuation to phase 3
Study: NCT05546359
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Standard of care treatment
Study: NCT06171958
Drug: Iodine-containing Contrast Media
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive or not receive ICM depending on their medical need.
Study: NCT04728880
Drug: Remdesivir
Normalized name: remdesivir
DrugBank: Remdesivir (DB14761)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: This study is a retrospective trial to assess the efficacy of Remdesivir in adult patients diagnosed with COVID-19 in Mansoura University Isolation Hospital. In this study we will analyze the data collected during treatment.
Study: NCT06277609
Drug: Lu AF28996
Normalized name: Lu-DOTA-TATE
DrugBank: Lutetium Lu 177 dotatate (DB13985)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule
Study: NCT06277609
Drug: Amoxicillin/clavulanic acid
DrugBank: Clavulanic acid (DB00766)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablet
Study: NCT02705313
Drug: 177Lu-DOTA0-Tyr3-Octreotate
Normalized name: 177Lu-DOTA-Tyr3-octreotate
DrugBank: Lutetium Lu 177 dotatate (DB13985)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The treatment regimen consists of 4 administrations of 7.4 GBq (200 mCi) at the date and time of infusion. The recommended interval between two infusions is 8 weeks, which could be extended up to 16 weeks in case of dose modifying toxicity.
Study: NCT06430736
Drug: Tocilizumab before CAR-T cell infusion
Normalized name: Anti-BCMA CAR T cell
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tocilizumab will be given at the standard-dose of 8 mg/kg b.w. intravenously, with completion of the infusion 1 hour prior to infusion of CAR-T cells.~Treatment of eventual subsequent CRS/ICANS will be identical as in patients in the standard arm.
Study: NCT06430736
Drug: Tocilizumab at emerging CRS
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tocilizumab will be given at the standard-dose of 8 mg/kg b.w. intravenously, and it will be repeated after 8 hours for a maximum of four administrations in patients with ongoing signs of CRS.
Study: NCT06384820
Drug: cemiplimab
Normalized name: CEMIPLIMAB
DrugBank: Cemiplimab (DB14707)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Administered Intravenous (IV) infusion every three weeks (Q3W)
Study: NCT06384820
Drug: fianlimab
Normalized name: Fianlimab
DrugBank: Fianlimab (DB18858)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion Q3W
Study: NCT05814146
Drug: Dialysate bicarbonate concentration
Normalized name: Potassium Bicarbonate
DrugBank: Potassium bicarbonate (DB11098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Assess how a lower dialysate bicarbonate affects:~* QTc duration during and between hemodialysis sessions~* PVC burden during and between hemodialysis sessions~* Clinically significant arrhythmia during and between hemodialysis sessions~* Intradialytic hypotension~* Adverse symptoms during hemodialysis sessions
Study: NCT05817903
Drug: Axitinib
Normalized name: Axitinib
DrugBank: Axitinib (DB06626)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Axitinib will be started at the standard dose of 5 mg BID until progression of disease, unacceptable toxicity, patient' or physician' decision.
Study: NCT05817903
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nivolumab will be administered at a flat dose of 480 mg IV every four weeks until progression of disease, unacceptable toxicity, patient' or physician' decision
Study: NCT04144933
Drug: Dexamethasone, Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 6 mg, 4 mg
Study: NCT04144933
Drug: Sevoflurane, Lidocaine 2% Injectable Solution, Ketamine, Dexmedetomidine, Magnesium Sulfate
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose titrated to effect, 1.5 mg/kg/hr, 0.15 mg/kg/hr, 0.3 -1 mcg/kg/hr (titrated to effect), 30 mg/kg bolus over 30 minutes
Study: NCT05517564
Drug: GM-60106
Normalized name: chloroxylenol 0.00106 MG/MG
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The participants will receive a single oral dose between 2.5 to 100 mg for Part A (SAD), Part B (MAD) once daily for 14 days, and for Part C (MAD) once daily for 28 days.
Study: NCT06300424
Drug: almonertinib
Normalized name: Almonertinib
DrugBank: Almonertinib (DB16640)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 110mg qd
Study: NCT06300424
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: AUC 5, d1 every 3 weeks
Study: NCT06300424
Drug: Nab paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 135 mg/m2, d1,d8 every 3 weeks
Study: NCT04144933
Drug: Lidocaine 1% Injectable Solution, Sufentanil
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.5 mg/kg, 0.25-0.5 mcg/kg (titrated to effect)
Study: NCT00345150
Drug: Ng-monomethyl-L-arginine (drug)
Normalized name: NG-Monomethyl-L-arginine
DrugBank: Tilarginine (DB11815)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05257915
Drug: Perampanel
Normalized name: Perampanel
DrugBank: Perampanel (DB08883)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: For patients ≥12 years old, the initial dose is 2 mg/d, and according to the clinical response and tolerance of the patient, the dose is increased to the minimum clinically effective dose in increments of 2 mg, and the interval between dose increases is not less than 2 weeks.~For patients \<12 years, according to the actual clinical situation, the initial dose and addition plan are judged by the investigator.
Study: NCT05071794
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antiemetic effect of propofol
Study: NCT04803877
Drug: Regorafenib 40 MG
Normalized name: regorafenib 40 MG
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: For subjects age 18 and older, Regorafenib will be administered as 80mg oral once daily on Cycle 1, Days 1-7 and then escalated to 120 mg once daily for Cycle 1, Days 8-21 if no Grade 2 or above regorafenib adverse events occur. For subsequent cycles, the highest tolerated dose will be taken once daily on days 1-21 of each 28-day cycle.
Study: NCT04803877
Drug: Regorafenib 20MG
Normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: For subjects younger than 18 years, Regorafenib will be administered as 60mg/m2/dose (rounded to the nearest 20mg, maximum dose of 80mg) once daily for Cycle 1, Days 8-21 if no Grade 2 or above regorafenib-related adverse events occur. For subsequent cycles, the highest tolerated dose will be taken once daily on days 1-21 of each 28-day cycle.
Study: NCT04803877
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: For subjects age 18 and older, Nivolumab will be administered at 480mg IV over 30 min every 28 days.~For subjects younger than 18 years, Nivolumab 3mg/kg (maximum dose 240mg) will be administered IV over 30 minutes on day 1 and 15 of each 28-day cycle.
Study: NCT00051571
Drug: SGN-15
Normalized name: SGN-15
DrugBank: SGN-15 (DB05818)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00051571
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05280275
Drug: Belantamab Mafodotin-Blmf
Normalized name: belantamab mafodotin-blmf
DrugBank: Belantamab mafodotin (DB15719)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Blmf will be available as 100 mg/vial in single-use vial for reconstitution, supplied as lyophilized powder.~Blmf will be delivered as IV solution over at least 30 minutes.
Study: NCT05280275
Drug: Daratumumab
Normalized name: Daratumumab
DrugBank: Daratumumab (DB09331)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Daratumumab will be administered with subcutaneous injections. On days where Blmf is given together with daratumumab, daratumumab should be performed first.
Study: NCT05280275
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lenalidomide will be administered per os.
Study: NCT05280275
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone will be administered intravenously or per os.
Study: NCT06238752
Drug: Apatinib Combined With Tislelizumab and Chemotherapy
Normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: apatinib (250 mg, qd, d1-14), tislelizumab(200 mg d1), and oxaliplatin (130 mg/m2, d1) plus oral capecitabine (1000 mg/m2, bid, d1-14) every 3 weeks
Study: NCT05790902
Drug: Silodosin
Normalized name: Silodosin
DrugBank: Silodosin (DB06207)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: The patients used Silodosin for Medical expulsive therapy of ureteric calculi
Study: NCT05790902
Drug: Tamsulosin
Normalized name: Tamsulosin
DrugBank: Tamsulosin (DB00706)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The patients used Tamsulosin for Medical expulsive therapy of ureteric calculi
Study: NCT05034146
Drug: 68Ga-FAPI
Normalized name: 68Ga-DOTATOC
DrugBank: Dotatate gallium Ga-68 (DB13925)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 68Ga-FAPI was injected intravenously to each subject, and the dose is calculated according to body weight of subject (approximately 1.85-3.7MBq/kg).
Study: NCT06276569
Drug: Sivelestat
Normalized name: Sivelestat
DrugBank: Sivelestat (DB12863)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: (1)Experimental group: Received intravenous sivelestat sodium within 6 hours of admission to the ICU. Sivelestat sodium was dissolved in 0.9% sodium chloride injection and a one-day dose (4.8mg/kg) was diluted in 50ml of 0.9% sodium chloride injection, which was then sealed for continuous intravenous administration at a rate of 0.2 mg/kg/h for seven consecutive days.
Study: NCT05650008
Drug: Intrathecal local anesthesia
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administration of local anesthetic into intrathecal space to achieve surgical anesthesia
Study: NCT05563168
Drug: DILTIAZEM TEVA 60 mg or placebo
Normalized name: INV-CSP #2002 METFORMIN OR PLACEBO
DrugBank: Diltiazem (DB00343)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DILTIAZEM TEVA 60 mg 3 times a day during 7 days + standard of care Or placebo 3 times a day during 7 days + standard of care.
Study: NCT00035308
Drug: Abetimus sodium (LJP 394)
Normalized name: abetimus
DrugBank: Abetimus (DB06662)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04513314
Drug: Valproate
Normalized name: Valproate
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Valproate sodium (enteral or intravenous) will be administered at a dosage of 10 to 15 mg/kg/day. The dosage may be increased by 5 to 10 mg/kg/week to achieve optimal clinical response. Ordinarily, optimal clinical response is achieved at daily doses below 60 mg/kg/day.
Study: NCT04513314
Drug: Quetiapine
Normalized name: Quetiapine
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enteral quetiapine dosing on Day 3: 25 mg to 50 mg twice daily. Increase in increments of 50 mg/day to 100 mg/day divided two on Days 4 and 5 to range of 50-400 mg/day by Day 7. Further adjustments can be made in increments of 25-50 mg twice a day, in intervals of not less than 2 days. Recommended dose range is 150-750 mg/day.
Study: NCT05591755
Drug: Brimonidine Tartrate 0.025%/ Ketotifen Fumarate 0.035% Ophthalmic Solution
DrugBank: Brimonidine (DB00484)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Brimonidine Tartrate 0.025%/ Ketotifen Fumarate 0.035% Ophthalmic Solution
Study: NCT05591755
Drug: Ketotifen fumarate ophthalmic solution 0.035% (n = 56)
DrugBank: Ketotifen (DB00920)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketotifen fumarate ophthalmic solution 0.035% (n = 56)
Study: NCT05591755
Drug: Brimonidine tartrate ophthalmic solution 0.025% (n = 56)
DrugBank: Brimonidine (DB00484)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Brimonidine tartrate ophthalmic solution 0.025% (n = 56)
Study: NCT00006198
Drug: thalidomide
Normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT06520306
Drug: Ropivacaine combined with methylene blue for iliac fascia block
Normalized name: Methylene Blue
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ultrasound-guided fascia iliaca block using different concentrations of methylene blue combined with ropivacaine
Study: NCT06331494
Drug: Butylphthalide
Normalized name: BUTYLPHTHALIDE
DrugBank: Butylphthalide (DB12749)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Butylphthalide Sodium Chloride injection for 10±3 days, oral Butylphthalide soft capsules for day 11±3 to day 180.
Study: NCT06394375
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: OFA
Study: NCT05953545
Drug: Peginterferon Lambda
Normalized name: Peginterferon lambda-1a
DrugBank: Peginterferon lambda-1a (DB14767)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study intervention for this protocol includes a weekly subcutaneous injection of peginterferon lambda at a dose of 180 mcg and an oral twice daily dosing of Lonafarnib at 50mg boosted with twice daily Ritonavir at 100mg for 48 weeks. Following 48 weeks of treatment the subjects will be monitored for outcomes during an additional 6-month time period.
Study: NCT00002298
Drug: Ribavirin
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT05510895
Drug: Binimetinib
Normalized name: binimetinib
DrugBank: Binimetinib (DB11967)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Triplet combination administered neoadjuvant and adjuvant, depending on TRG
Study: NCT05260359
Drug: 6% Bemotrizinol (BEMT) in a basic sunscreen oil formulation
DrugBank: Bemotrizinol (DB11206)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SU E 101413 85
Study: NCT05260359
Drug: 6% Bemotrizinol (BEMT) dispersion in petrolatum
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SU-E-101413-82
Study: NCT05915546
Drug: Emraclidine
Normalized name: Emraclidine
DrugBank: Emraclidine (DB18706)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets
Study: NCT05794425
Drug: Cyclosporine A
Normalized name: CycloSPORINE A
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-5 mg per kilogram per day.
Study: NCT05566535
Drug: Ruxolitinib
Normalized name: Ruxolitinib
DrugBank: Ruxolitinib (DB08877)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ruxo will be administered to patients with PV in a real-world setting. Treatment with Ruxo is according to local approved label. Ruxo treatment should be administered according to drug official instruction and in compliance with clinical practice at the certain medical center.
Study: NCT05616052
Drug: Semaglutide
Normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: treatment with different dosage regimes
Study: NCT06193837
Drug: Augmentin
Normalized name: Augmentin
DrugBank: Clavulanic acid (DB00766)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Use of prophylactic antibiotics in lap cholecystectomy
Study: NCT06452537
Drug: Tocilizumab
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tocilizumab will be intravenously administered as the dosage of 8 mg/kg every 4 weeks, with oral prednisone.
Study: NCT06452537
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone tapering protocol : If the starting dose is over 20mg/day, then reduce by one tablet weekly. Until the dose is reduced to 20mg/day then 20mg/day for two weeks→17.5mg/day for two weeks→12.5mg for four weeks→10mg for four weeks→7.5mg as a maintain dosage
Study: NCT05232461
Drug: PrimeC-ER 748 mg
Normalized name: trenbolone
DrugBank: Trenbolone (DB11551)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PrimeC-ER is an extended release formulation of a fixed dose combination of ciprofloxacin and celecoxib
Study: NCT05232461
Drug: Ciprofloxacin 750 MG
Normalized name: ciprofloxacin 750 MG
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciprofloxacin
Study: NCT04785222
Drug: dexmedetomidine 5 mcg mixed with 0.5% plain bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bilateral infraorbital nerve block with dexmedetomidine 5 mcg mixed with 0.5% plain bupivacaine, in total volume of 2 ml per side
Study: NCT00000994
Drug: Zidovudine
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT06248229
Drug: Dyanavel XR
Normalized name: Dyanavel XR
DrugBank: Amphetamine (DB00182)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosing will begin the morning following Visit 2. Subjects in the active group will begin the study on 5 mg of Dyanavel XR. Subjects will be advised to take one capsule each morning upon awakening, dosed consistently with respect to time. Subjects will be advised that tablets should be swallowed whole, not crushed, chewed, or cut. Subjects can take Dyanavel XR with or without food.~Subjects will return to the study site on a weekly (and later, bi-weekly) basis for evaluation of symptoms and possible side effects. Subjects will be titrated to their optimal dose based on the dose titration schedule displayed in Section 5.1. The PI will be available to consult with patients as needed between Week 0 and Week 4 to adjust dosage per the PI's clinical judgment.
Study: NCT06373835
Drug: Emodepside
Normalized name: Emodepside
DrugBank: Emodepside (DB11403)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg tablets of emodepside and matching placebo tablets, 3mg ivermectin
Study: NCT06106685
Drug: High-dose washed microbiota suspension
Normalized name: Washed Microbiota Transplantation
DrugBank: Washed Microbiota Transplantation (DB15745)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The high-dose group will be administered a high dose of washed microbiota suspension。